This is particularly relevant because temsirolimus is an active agent against AML progenitor cells (including leukemia-initiating cells) both in vitro and in vivo when used in combination with the NF-κB inhibitor parthenolide (PTL), a naturally occurring small molecule [63] or clofarabine [64]. This evidence concerns the gene NFKB1 and leukemia.